Engrail Therapeutics has initiated the Phase II ENCALM clinical trial of ENX-102 for the treatment of patients with generalised anxiety disorder (GAD).
The multi-centre, placebo-controlled, randomised, double-blind study intends to assess the safety and efficacy of ENX-102 alone in GAD patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Male or female patients aged 18 to 65 years diagnosed with GAD are administered with a 2mg ENX-102 capsule for four weeks.
They are then followed for three weeks, including a tapered dose week and two weeks of a placebo in capsule form given once daily in the evening, for a nine-week total treatment period.
The placebo group is dosed once daily in the evening for six weeks out of a nine-week period.
Engrail Therapeutics chief scientific officer Kimberly Vanover said: “Translational and Phase I clinical data indicate central target engagement, with a highly differentiated safety and tolerability profile for ENX-102 against non-selective GABA-A positive allosteric modulators (PAMs) such as benzodiazepines.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“ENX-102 exhibits a long half-life and can be dosed once daily, without titration. These data support further evaluation of ENX-102 for efficacy in generalised anxiety disorder.”
ENX-102 is an investigational, subtype-selective, gamma-aminobutyric acid A (GABA-A) PAM that enhances the neurotransmission of GABA in α2, α3, and α5 receptors while blocking α1.
Engrail CEO and president Vikram Sudarsan said: “The initiation of Phase II and further advancement of the rest of our precision neuroscience pipeline makes 2023 a hallmark year for the organisation.”
The company is also engaged in developing transformational therapies that improve the lives of patients with neurodevelopmental, neuropsychiatric, and neurologic disorders.
